輸入代號或公司名稱後按 Enter
MGNX

MACROGENICS INC

+0.01 (+0.37%)前一交易日收盤 2026-09-17
美股 · Nasdaq · 製藥生技 · 製藥SIC 2834
4.10USD193K成交股數261M市值本益比(近四季)1.4股價營收比+378.0%營收年增(近四季)2026-11-12下次財報

財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束

逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。

營收與利潤率近 16 季

稀釋 EPS近 16 季 · 美元

現金流近 16 季

股東回饋近 16 季 · 庫藏股與股利

損益表 逐季 · 最新在左 · 小字是年增率

科目26Q226Q125Q425Q325Q225Q124Q324Q224Q123Q423Q323Q2
營收32.8M+378%20.8M+57%56.6M-49%72.8M+575%6.9M-25%13.2M+23%111M+965%10.8M-18%9.1M10.7M10.4M13.1M
營業成本0.000.000.000.00168K176K270K163K85K258K
毛利56.6M-49%72.8M+586%6.9M-22%13.2M+25%111M+972%10.6M-18%8.8M10.6M10.3M12.9M
毛利率100.0%100.0%100.0%100.0%99.8%98.4%97.0%98.5%99.2%98.0%
研發費用38.8M35.0M34.0M32.7M40.8M39.7M40.5M51.7M46.0M47.4M30.1M43.2M
銷售管理費用7.9M9.7M9.2M9.9M9.3M10.7M14.1M14.4M14.7M12.6M12.4M13.7M
營業利益−13.9M-68%−33.4M-22%−5.6M-110%18.6M-132%−43.2M-20%−42.6M-14%54.2M-253%−58.2M+29%−53.8M−49.4M−35.5M−45.0M
營業利益率-42.2%-161.0%-9.9%25.6%-629.3%-323.1%48.9%-538.9%-590.4%-460.4%-341.5%-342.3%
稅後淨利19.5M-154%−36.8M-10%60.4M+7%16.8M-130%−36.3M-31%−41.0M+11%56.3M+221%−55.7M-197%−52.2M−37.0M17.6M57.5M
淨利率59.4%-177.0%106.7%23.1%-527.7%-311.1%50.9%-515.6%-573.3%-345.4%168.8%437.5%
稀釋 EPS0.31-154%-0.58-11%-0.23-126%0.27-130%-0.57-32%-0.65-12%0.90+221%-0.89-197%-0.84-0.740.280.92
稀釋股數63.6M63.4M63.2M63.3M63.1M63.0M62.9M62.7M62.3M61.9M62.2M62.3M

資產負債表 期末餘額

科目26Q226Q125Q425Q325Q225Q124Q324Q224Q123Q423Q323Q2
現金與約當現金114M66.5M57.2M80.1M131M146M180M83.9M80.4M101M89.9M109M
應收帳款24.6M10.4M427K69.2M12.5M10.5M8.8M6.2M7.2M10.4M25.3M6.4M
存貨9.5M7.9M8.8M9.3M9.4M3.2M1.1M1.2M1.2M1.1M1.4M
總資產345M218M257M271M245M225M264M201M248M298M340M306M
有息負債
總負債303M197M201M204M199M145M144M143M142M146M146M134M
股東權益42.9M21.2M55.6M67.0M46.6M79.1M120M57.8M106M153M194M172M
負債比87.6%90.3%78.4%75.3%81.0%64.8%54.6%71.3%57.2%48.9%42.9%43.9%
淨現金(現金 − 有息負債)

現金流量表 單季

科目26Q226Q125Q425Q325Q225Q124Q324Q224Q123Q423Q323Q2
營業現金流−35.8M-24%−46.9M−45.6M
資本支出344K529K1.5M
自由現金流−36.2M-24%−47.4M−47.1M
折舊攤銷1.7M1.8M1.8M
買回庫藏股
現金股利
自由現金流率-174.0%-359.5%-517.4%

營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度

產品/服務2025 年度 · 150M
Revenue From Collaborative Agreements87.2M58.3%-27.3%
Contract Manufacturing52.6M35.2%+303.1%
Revenue From Royality Agreements9.7M6.5%+1626.6%

各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。

年度 10-K

財年營收年增稅後淨利淨利率稀釋 EPS自由現金流
FY2025150M-0.3%−75K-0.0%-1.18−83.0M
FY2024150M+155.3%−67K-0.0%-1.07−72.1M
FY202358.7M-61.3%−9K-0.0%-0.15−80.0M
FY2022152M+96.2%−120M-78.8%-1.95−90.6M
FY202177.4M-26.2%−202M-261.0%-3.37−150M
FY2020105M+63.4%−130M-123.7%-2.47−118M
FY201964.2M+6.8%−152M-236.5%−139M
FY201860.1M−171M-285.2%−178M